Polycythemia Vera
Polycythemia Vera
Patrick DalyPolycythemia Vera | December 8, 2023
Rusfertide quickly induced hematocrit control and maintained improved levels over time in patients with polycythemia vera.
Read More
Blood Cancers Today Staff WritersMyeloproliferative Neoplasms | December 6, 2023
Researchers analyzed PV patients allocated to the ropeginterferon alfa-2b arm of the PROUD-PV/CONTINUATION-PV studies.
Melissa BadamoPolycythemia Vera | November 28, 2023
CR rates were comparable in both treatment groups, but OS was superior in the ruxolitinib group.
Leah SherwoodMyelofibrosis | October 11, 2023
Nearly all myelofibrosis patients are estimated to develop anemia over the course of the disease.
Cailin ConnerMeeting News | September 10, 2023
The need for phlebotomies substantially decreased in those who received ruxolitinib after hydroxyurea.
Cailin ConnerMeeting News | September 10, 2023
The combined average cost for the index hospitalization and two-year TE-related readmissions was $30,285.
Cailin ConnerPolycythemia Vera | September 9, 2023
The investigators sought to investigate the diagnostic landscape of polycythemia vera in LMICs.
Cecilia BrownMyeloproliferative Neoplasms | September 9, 2023
Researchers presented data from the randomized withdrawal phase of the study at the SOHO Annual Meeting.
Leah SherwoodIndolent B-Cell Lymphoma | October 15, 2023
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
Leah SherwoodPolycythemia Vera | July 6, 2023
Dr. Harrison discusses survey results from the LANDMARK survey in patients with polycythemia vera and their physicians.
Cecilia BrownMyeloproliferative Neoplasms | July 10, 2023
Just under half (43%) of patients receiving ruxolitinib achieved a CR, while 26% achieved a CR on the best available therapy.
Cecilia BrownPolycythemia Vera | June 26, 2023
The trial included patients with PV who had at least three therapeutic phlebotomies in the 28 weeks prior to enrollment.
Cecilia BrownMeeting News | June 14, 2023
Dr. Kuykendall and colleagues presented their findings during the 2023 European Hematology Association Congress.
Leah SherwoodVideo Insights | June 14, 2023
Dr. Krecak presented the research during the 2023 EHA Congress.
Leah SherwoodMyeloproliferative Neoplasms | June 13, 2023
The main aim of treatment is preventing thrombotic complications.
Leah SherwoodMyeloproliferative Neoplasms | May 30, 2023
The FDA could not approve the application in its current form and identified additional requirements for approval.
Cecilia BrownMyeloproliferative Neoplasms | May 30, 2023
Hematocrit control was “suboptimal” in more than half of patients with high-risk polycythemia vera.
Leah SherwoodMeeting News | May 30, 2023
Srdan Verstovsek, MD, discusses using machine learning to predict resistance to hydroxyurea therapy in polycythemia vera.
Cecilia BrownMyeloproliferative Neoplasms | May 30, 2023
Patients with MPN have a high risk of death from cardiovascular causes.
Leah SherwoodVideo Insights | May 30, 2023
Srdan Verstovsek, MD, discusses the phase III VERIFY trial of rusfertide in patients with polycythemia vera.
Editorial Board